Does interleukin-18 or tumour necrosis factor-α have an independent association with the risk of coronary heart disease? Results from a prospective study in New Zealand

Cytokine

Volumn 50, Issue 1, 2010, Pages 94-98

  Welsh, Paul ^a   Woodward, Mark ^a,b,c   Rumley, Ann ^a   MacMahon, Steve ^b   Lowe, Gordon D ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF SYDNEY   (Australia)

^c MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

Coronary heart disease; IL 18; Inflammation; Risk markers; TNF

Indexed keywords

C REACTIVE PROTEIN; FIBRINOGEN; INTERLEUKIN 18; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGE DISTRIBUTION; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY RISK; DISEASE ASSOCIATION; FEMALE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; NEW ZEALAND; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; SEX DIFFERENCE;

CASE-CONTROL STUDIES; CORONARY DISEASE; FOLLOW-UP STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INTERLEUKIN-18; NEW ZEALAND; ODDS RATIO; PROSPECTIVE STUDIES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77049113718     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cyto.2009.12.014     Document Type: Article

References (31)

1. Danesh J., Wheeler J.G., Hirschfield G.M., Eda S., Eiriksdottir G., Rumley A., et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 350 (2004) 1387-1397
2. Stuyt R.J., Netea M.G., Verschueren I., Dinarello C.A., Kullberg B.J., and van der Meer J.W. Interleukin-18 does not modulate the acute-phase response. J Endotoxin Res 11 (2005) 85-88
3. Sattar N., and McInnes I.B. Vascular comorbidity in rheumatoid arthritis: potential mechanisms and solutions. Curr Opin Rheumatol 17 (2005) 286-292
4. Canault M., Peiretti F., Mueller C., Kopp F., Morange P., Rihs S., et al. Exclusive expression of transmembrane TNF-alpha in mice reduces the inflammatory response in early lipid lesions of aortic sinus. Atherosclerosis 172 (2004) 211-218
5. Mallat Z., Corbaz A., Scoazec A., Besnard S., Leseche G., Chvatchko Y., et al. Expression of interleukin-18 in human atherosclerotic plaques and relation to plaque instability. Circulation 104 (2001) 1598-1603
6. Whitman S.C., Ravisankar P., and Daugherty A. Interleukin-18 enhances atherosclerosis in apolipoprotein E(-/-) mice through release of interferon-gamma. Circ Res 90 (2002) E34-E38
7. Blankenberg S., Luc G., Ducimetiere P., Arveiler D., Ferrieres J., Amouyel P., et al. Interleukin-18 and the risk of coronary heart disease in European men: the prospective epidemiological study of myocardial infarction (PRIME). Circulation 108 (2003) 2453-2459
8. Blankenberg S., McQueen M.J., Smieja M., Pogue J., Balion C., Lonn E., et al. Comparative impact of multiple biomarkers and N-terminal pro-brain natriuretic peptide in the context of conventional risk factors for the prediction of recurrent cardiovascular events in the heart outcomes prevention evaluation (HOPE) Study. Circulation 114 (2006) 201-208
9. Blankenberg S., Tiret L., Bickel C., Peetz D., Cambien F., Meyer J., et al. Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina. Circulation 106 (2002) 24-30
10. Koenig W., Khuseyinova N., Baumert J., Thorand B., Loewel H., Chambless L., et al. Increased concentrations of C-reactive protein and IL-6 but not IL-18 are independently associated with incident coronary events in middle-aged men and women: results from the MONICA/KORA Augsburg case-cohort study, 1984-2002. Arterioscler Thromb Vasc Biol 26 (2006) 2745-2751
11. Espinola-Klein C., Rupprecht H.J., Bickel C., Lackner K., Schnabel R., Munzel T., et al. Inflammation, atherosclerotic burden and cardiovascular prognosis. Atherosclerosis 195 (2007) e126-e134
12. Kip K.E., Marroquin O.C., Shaw L.J., Arant C.B., Wessel T.R., Olson M.B., et al. Global inflammation predicts cardiovascular risk in women: a report from the women's ischemia syndrome evaluation (WISE) study. Am Heart J 150 (2005) 900-906
13. Tiret L., Godefroy T., Lubos E., Nicaud V., Tregouet D.A., Barbaux S., et al. Genetic analysis of the interleukin-18 system highlights the role of the interleukin-18 gene in cardiovascular disease. Circulation 112 (2005) 643-650
14. Everett B.M., Bansal S., Rifai N., Buring J.E., and Ridker P.M. Interleukin-18 and the risk of future cardiovascular disease among initially healthy women. Atherosclerosis 202 1 (2009) 282-288
15. Hung J., Knuiman M.W., Divitini M.L., Langton P.E., Chapman C.L., and Beilby J.P. C-reactive protein and interleukin-18 levels in relation to coronary heart disease: prospective cohort study from Busselton Western Australia. Heart Lung Circ 17 (2008) 90-95
16. Woodward M., Welsh P., Rumley A., Tunstall-Pedoe H., and Lowe G.D. Do inflammatory biomarkers add to the discrimination of cardiovascular disease after allowing for social deprivation? Results from a 10 year cohort study in Glasgow, Scotland. Eur Heart J. (2009) [Epub ahead of print PMID: 19363058]
17. Cesari M., Penninx B.W., Newman A.B., Kritchevsky S.B., Nicklas B.J., and Sutton-Tyrrell K. Inflammatory markers and onset of cardiovascular events: results from the health ABC study. Circulation 108 (2003) 2317-2322
18. Koukkunen H., Penttila K., Kemppainen A., Halinen M., Penttila I., Rantanen T., et al. C-reactive protein, fibrinogen, interleukin-6 and tumour necrosis factor-alpha in the prognostic classification of unstable angina pectoris. Ann Med 33 (2001) 37-47
19. Ridker P.M., Rifai N., Pfeffer M., Sacks F., Lepage S., and Braunwald E. Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation 101 (2000) 2149-2153
20. Sukhija R., Fahdi I., Garza L., Fink L., Scott M., Aude W., et al. Inflammatory markers, angiographic severity of coronary artery disease, and patient outcome. Am J Cardiol 99 (2007) 879-884
21. Tuomisto K., Jousilahti P., Sundvall J., Pajunen P., and Salomaa V. C-reactive protein, interleukin-6 and tumor necrosis factor alpha as predictors of incident coronary and cardiovascular events and total mortality. A population-based, prospective study. Thromb Haemost 95 (2006) 511-518
22. MacMahon S., Norton R., Jackson R., Mackie M.J., Cheng A., Vander Hoorn S., et al. Fletcher Challenge - University of Auckland Heart & Health Study: design and baseline findings. N Z Med J 108 (1995) 499-502
23. Woodward M., Rumley A., Welsh P., MacMahon S., and Lowe G. A comparison of the associations between seven hemostatic or inflammatory variables and coronary heart disease. J Thromb Haemost 5 (2007) 1795-1800
24. Woodward M. Epidemiology: study design and data analysis. 2nd ed. (2005), Chapman and Hall/CRC Press, Boca Raton
25. Welsh P., Woodward M., Rumley A., and Lowe G. Associations of circulating TNFalpha and IL-18 with myocardial infarction and cardiovascular risk markers: the Glasgow Myocardial Infarction Study. Cytokine 47 (2009) 143-147
26. Welsh P., Woodward M., Rumley A., and Lowe G. Associations of plasma pro-inflammatory cytokines, fibrinogen, viscosity and C-reactive protein with cardiovascular risk factors and social deprivation: the fourth Glasgow MONICA study. Br J Haematol 141 (2008) 852-861
27. Schreyer S.A., Vick C.M., and LeBoeuf R.C. Loss of lymphotoxin-alpha but not tumor necrosis factor-alpha reduces atherosclerosis in mice. J Biol Chem 277 (2002) 12364-12368
28. Sattar N., Murray H.M., Welsh P., Blauw G.J., Buckley B.M., Cobbe S., et al. Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) Study Group. Are markers of inflammation more strongly associated with risk for fatal than for nonfatal vascular events?. PLoS Med 6 (2009) e1000099
29. Dixon W.G., Watson K.D., Lunt M., and Hyrich K.L. British Society for Rheumatology Biologics Register Control Centre Consortium, Silman AJ, Symmons DP; British Society for Rheumatology Biologics Register. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 56 (2007) 2905-2912
30. Beutler B.A., Milsark I.W., and Cerami A. Cachectin/tumor necrosis factor: production, distribution, and metabolic fate in vivo. J Immunol 135 6 (1985) 3972-3977
31. Hosohara K., Ueda H., Kashiwamura S., Yano T., Ogura T., Marukawa S., et al. Interleukin-18 induces acute biphasic reduction in the levels of circulating leukocytes in mice. Clin Diagn Lab Immunol 9 4 (2002) 777-783